Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Acer Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 23 full-time employees. The firm is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The firm is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The firm is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The firm is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Website: acertx.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 50.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 058.7%. On average the margin is decreasing steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 12 110.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 16.8% higher than minimum and 72.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued >100x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ACER
Share price, USD:  (0.0%)0.6601
year average price 0.6601  


year start price 0.6601 2025-01-21

max close price 0.6601 2025-01-21

min close price 0.6601 2025-01-21

current price 0.6601 2026-01-21
Common stocks: 14 310 244

Dividend Yield:  0.0%
EV / Sales: -6.4x
Margin (EBITDA LTM / Revenue): -1 058.7%
Fundamental value created in LTM:
Market Cap ($m): 9
Net Debt ($m): -13 838
EV (Enterprise Value): -13 829
Price to Book: -0.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-10-20CNBC

PC demand is back, says Acer CEO who sees robust growth in the 'foreseeable future'

2023-09-01Zacks Investment Research

Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up

2023-08-31InvestorPlace

Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ACER ACER ACER ACER ACER ACER
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-20 2023-08-14 2023-05-15 2023-03-27 2022-11-14 2022-08-15
acceptedDate 2023-11-20 16:51:15 2023-08-14 16:19:37 2023-05-15 17:18:16 2023-03-27 16:11:13 2022-11-14 17:23:55 2022-08-15 17:01:26
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 371 790 0 0 0 0 0
costOfRevenue 83 805 0 0 0 0 0
grossProfit 287 985 0 0 0 0 0
grossProfitRatio 0.775 0 0 0 0 0
researchAndDevelopmentExpenses 2M 1M 2M 3M 3M 3M
generalAndAdministrativeExpenses 0 3M 3M 3M 3M 4M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 3M 3M 3M 3M 4M
otherExpenses 7M 0 -577 225 -229 500 0 -200 129
operatingExpenses 13M 4M 5M 5M 5M 7M
costAndExpenses 13M 4M 5M 5M 5M 7M
interestIncome 0 0 0 0 0 0
interestExpense -133 000 0 -286 537M 82 001 19 431 0
depreciationAndAmortization -39 586 9929 15 547 4M -321 089 18 190
ebitda -13M -9M 5M -1M -6M -3M
ebitdaratio -34.638 0 0 0 0 0
operatingIncome -13M -4M 5M -5M -5M -7M
operatingIncomeRatio -34.638 0 0 0 0 0
totalOtherIncomeExpensesNet -2M -4M -22M -4M 232 105 5M
incomeBeforeTax -15M -8M -16M -9M -5M -3M
incomeBeforeTaxRatio -39.622 0 0 0 0 0
incomeTaxExpense 0 0 11 577 942M 2M -19 431 0
netIncome -15M -8M -11 577 958M -11M -5M -3M
netIncomeRatio -39.622 0 0 0 0 0
eps -0.6 -0.33 -548 376 -0.65 -0.31 -0.17
epsdiluted -0.6 -0.33 -548 376 -0.65 -0.31 -0.17
weightedAverageShsOut 24M 24M 21M 17M 16M 15M
weightedAverageShsOutDil 24M 24M 21M 17M 16M 15M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ACER ACER ACER ACER ACER ACER
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-20 2023-08-14 2023-05-15 2023-03-27 2022-11-14 2022-08-15
acceptedDate 2023-11-20 16:51:15 2023-08-14 16:19:37 2023-05-15 17:18:16 2023-03-27 16:11:13 2022-11-14 17:23:55 2022-08-15 17:01:26
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 594 659 2M 6M 2M 6M 14M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 594 659 2M 6M 2M 6M 14M
netReceivables 0 0 800 777 0 0 0
inventory 5M 5M 412 038 0 0 0
otherCurrentAssets 343 556 597 977 14 638 20 188 5436 731 379
totalCurrentAssets 6M 7M 8M 4M 7M 15M
propertyPlantEquipmentNet 40 976 54 273 202 097 214 578 92 502 101 582
goodwill 8M 8M 8M 8M 8M 8M
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 8M 8M 8M 8M 8M 8M
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 173 010 194 725 215 302 245 683 280 695 292 918
totalNonCurrentAssets 8M 8M 8M 8M 8M 8M
otherAssets 0 0 0 0 0 0
totalAssets 14M 15M 16M 12M 15M 23M
accountPayables 7M 6M 2M 4M 5M 3M
shortTermDebt 18M 32M 29M 2M 2M 2M
taxPayables 0 0 0 0 0 0
deferredRevenue 0 5M 0 0 0 0
otherCurrentLiabilities 37M 6M 8M 13M 15M 12M
totalCurrentLiabilities 62M 43M 38M 19M 21M 17M
longTermDebt 0 100 836 123 509 9M 7M 7M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 -122M 0 0
otherNonCurrentLiabilities 77M 4M 4M 122M 540 025 8M
totalNonCurrentLiabilities 77M 4M 4M 9M 7M 15M
otherLiabilities -77M 0 0 0 0 0
capitalLeaseObligations 0 0 228 332 249 590 167 321 166 134
totalLiabilities 62M 48M 42M 28M 28M 32M
preferredStock 0 0 0 0 0 0
commonStock 2446 2446 2342 1962 1637 1567
retainedEarnings -180M -165M -157M -141M -131M -126M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0
othertotalStockholdersEquity 132M 132M 131M 124M 119M 118M
totalStockholdersEquity -48M -33M -26M -17M -12M -9M
totalEquity -48M -33M -26M -17M -12M -9M
totalLiabilitiesAndStockholdersEquity 14 002M 15M 16M 12M 15M 23M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 14 002M 15M 16M 12M 15M 23M
totalInvestments 0 0 0 0 0 0
totalDebt 18M 32M 29M 12M 8M 9M
netDebt 18M 31M 22M 10M 2M -6M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ACER ACER ACER ACER ACER ACER
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-20 2023-08-14 2023-05-15 2023-03-27 2022-11-14 2022-08-15
acceptedDate 2023-11-20 16:51:15 2023-08-14 16:19:37 2023-05-15 17:18:16 2023-03-27 16:11:13 2022-11-14 17:23:55 2022-08-15 17:01:26
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -16M -8M -16M -9M -5M -3M
depreciationAndAmortization 0 9929 15 547 13 254 13 985 18 190
deferredIncomeTax 0 487 895 0 0 0 0
stockBasedCompensation 0 259 903 285 509 445 510 460 115 460 777
changeInWorkingCapital 0 -977 734 -4M -3M -4M -3M
accountsReceivables 0 1M 0 -5M 0 0
inventory 0 -4M -412 038 0 0 0
accountsPayables 0 4M -2M -874 233 1M 1M
otherWorkingCapital 0 -2M -1M 2M -6M -5M
otherNonCashItems 285 509 3M 11M 4M -202 150 0
netCashProvidedByOperatingActivities -16M -6M -9M -8M -9M -10M
investmentsInPropertyPlantAndEquipment 0 0 -3066 -135 330 -4905 -2005
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 -3066 -135 330 -4905 -2005
debtRepayment 0 0 -98 655 -724 929 0 0
commonStockIssued 6M 347 613 6M 4M 1M 4M
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 6M 677 628 7M 724 929 0 -1
netCashUsedProvidedByFinancingActivities 6M 677 628 13M 4M 1M 4M
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash -10M -5M 4M -4M -8M -6M
cashAtEndOfPeriod -10M 2M 6M 2M 6M 14M
cashAtBeginningOfPeriod 0 6M 2M 6M 14M 21M
operatingCashFlow -16M -6M -9M -8M -9M -10M
capitalExpenditure 0 0 -3066 -135 330 -4905 -2005
freeCashFlow -16M -6M -9M -8M -9M -10M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2023-11-20 16:51 ET
Acer Therapeutics reported for 2023 q3
SEC form 10
2023-11-20 00:00 ET
Acer Therapeutics reported for 2023 q3
SEC form 10
2023-08-14 16:19 ET
Acer Therapeutics reported for 2023 q2
SEC form 6
2023-08-14 16:09 ET
Acer Therapeutics reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Acer Therapeutics reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Acer Therapeutics reported for 2023 q2
SEC form 6
2023-06-26 09:00 ET
Acer Therapeutics published news for 2023 q1
SEC form 10
2023-05-15 17:18 ET
Acer Therapeutics reported for 2023 q1
SEC form 6
2023-05-15 17:10 ET
Acer Therapeutics reported for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Acer Therapeutics reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Acer Therapeutics reported for 2023 q1
SEC form 6
2023-05-03 17:33 ET
Acer Therapeutics published news for 2023 q1
SEC form 6
2023-05-01 09:00 ET
Acer Therapeutics published news for 2023 q1
SEC form 6
2023-04-27 06:06 ET
Acer Therapeutics published news for 2023 q1
SEC form 6
2023-04-14 16:25 ET
Acer Therapeutics published news for 2023 q1
SEC form 10
2023-03-27 16:11 ET
Acer Therapeutics reported for 2022 q4
SEC form 6
2023-03-27 16:03 ET
Acer Therapeutics reported for 2022 q4
SEC form 8
2023-03-27 00:00 ET
Acer Therapeutics reported for 2022 q4
SEC form 10
2023-03-27 00:00 ET
Acer Therapeutics reported for 2022 q4
SEC form 6
2023-03-22 16:01 ET
Acer Therapeutics published news for 2022 q4
SEC form 6
2023-03-17 09:00 ET
Acer Therapeutics published news for 2022 q4
SEC form 6
2023-03-15 09:00 ET
Acer Therapeutics published news for 2022 q4
SEC form 10
2022-11-14 00:00 ET
Acer Therapeutics reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Acer Therapeutics reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Acer Therapeutics published news for 2022 q3
SEC form 8
2022-08-15 00:00 ET
Acer Therapeutics reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Acer Therapeutics reported for 2022 q2
SEC form 8
2022-05-16 00:00 ET
Acer Therapeutics reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Acer Therapeutics reported for 2022 q1
SEC form 8
2022-03-02 00:00 ET
Acer Therapeutics published news for 2021 q4
SEC form 10
2022-03-02 00:00 ET
Acer Therapeutics published news for 2021 q4
SEC form 8
2021-11-19 00:00 ET
Acer Therapeutics published news for 2021 q3
SEC form 10
2021-11-19 00:00 ET
Acer Therapeutics published news for 2021 q3
SEC form 8
2021-11-16 00:00 ET
Acer Therapeutics published news for 2021 q3
SEC form 10
2021-08-10 00:00 ET
Acer Therapeutics published news for 2021 q2
SEC form 10
2021-05-17 00:00 ET
Acer Therapeutics published news for 2021 q1